Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-02
2006-05-02
Low, Christopher S. F. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07037936
ABSTRACT:
The present invention generally relates to compounds and compositions useful for the modulation of ligase activity. The invention further relates to Compounds of the Invention, compositions thereof, and methods for treating or preventing cancer, a neoplastic disorder, acute or chronic renal failure, an inflammatory disorder, an immune disorder, a cardiovascular disease, an effect of aging or an infectious disease comprising administering an effective amount of a Compound of the Invention. The invention further relates to the use of a Compound of the Invention as a preservative of a cell, blood, tissue or an organ or as an agent to modulate stem cells.
REFERENCES:
patent: 3328249 (1967-06-01), Aceto et al.
patent: WO 93/15047 (1993-08-01), None
patent: WO 00/12679 (2000-03-01), None
patent: WO 00/34447 (2000-06-01), None
patent: WO 02/55665 (2002-07-01), None
Goldman et al. (Editors) “Principles of Cancer Therapy”. Cecil's Textbook of Medicine (Twenty-First Edition). W.B. Saunders Company, 2000. p. 1060-1074.
STN Accession No. 1982:199191. Leclerc et al. “Synthesis and Cardiovascular Activity of a New Series of Cyclohexylaralkylamine Derivatives Related to Perhexiline”. Journal of Medicinal Chemistry. 1982; 25(6); 709-714. (pp. 1-11).
STN Accession No. 1967:499834. Aceto et al. “Compounds for Counteracting Depressive States”. Abstract of U.S. Patent No. 3328249 Issued 1967. (pp. 1-7).
Alessandrini et al., 1997, “Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation,” Leukemia. 11(3):342-345. Review.
Ganoth et al., 2001, “The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27,” Nat Cell Biol. 3(3):321-324.
Goukassian et al., 2001, “Overexpression of p27(Kip1) by doxycycline-regulated adenoviral vectors inhibits endothelial cell proliferation and migration and impairs angiogenesis,” FASEB J. 15(11):1877-1885.
Kwon et al., 1997, “Overexpression of cyclin E and cyclin-dependent kinase inhibitor (p27Kip1): effect on cell cycle regulation in HeLa cells,” Biochem Biophys Res Commun. 238(2):534-538.
Pagano, 1997, “Cell cycle regulation by the ubiquitin pathway,” FASEB J. 11(13):1067-1075, Review.
Pagano et al., 1995, “Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27,” Science 269(5224):682-685.
Sheaff et al., 1997, “Cyclin E-CDK2 is a regulator of p27Kip1,” Genes Dev. 1997 11(11):1464-1478.
Yu et al., 1998, “Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21 (CIP1/WAF1) and cyclin D proteins,” Proc Natl Acad Sci U S A. 95(19):11324-11329.
McKenna Jeffrey
Mercurio Frank
Pagano Michele
Plantevin Veronique
Xie Weilin
Jones Day
Low Christopher S. F.
Royds Leslie A
Signal Pharmaceuticals, LLC.
LandOfFree
Compounds useful for the treatment of cancer, compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds useful for the treatment of cancer, compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds useful for the treatment of cancer, compositions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3578857